PUBLICATION

Chemical screens in a zebrafish model of CHARGE syndrome identifies small molecules that ameliorates disease like phenotypes in embryo

Authors
Asad, Z., Sachidanandan, C.
ID
ZDB-PUB-190507-30
Date
2019
Source
European Journal of Medical Genetics   63(2): 103661 (Journal)
Registered Authors
Sachidanandan, Chetana
Keywords
CHARGE syndrome, CHD7, CHIC-35, DAPT, Drug discovery, M344, Procainamide, Zebrafish
MeSH Terms
  • Animals
  • Animals, Genetically Modified
  • CHARGE Syndrome/drug therapy*
  • CHARGE Syndrome/genetics
  • CHARGE Syndrome/physiopathology*
  • Cartilage/drug effects
  • Cartilage/pathology
  • DNA (Cytosine-5-)-Methyltransferase 1/antagonists & inhibitors
  • DNA Helicases/genetics*
  • DNA Helicases/metabolism
  • DNA-Binding Proteins/genetics*
  • DNA-Binding Proteins/metabolism
  • Dipeptides/pharmacology*
  • Dipeptides/therapeutic use
  • Disease Models, Animal
  • Embryo, Nonmammalian/diagnostic imaging
  • Embryo, Nonmammalian/drug effects
  • Embryo, Nonmammalian/metabolism
  • Embryo, Nonmammalian/physiopathology
  • Gene Knockdown Techniques
  • Histone Deacetylase Inhibitors/pharmacology
  • Histone Deacetylase Inhibitors/therapeutic use
  • LIM-Homeodomain Proteins/genetics
  • LIM-Homeodomain Proteins/metabolism
  • Nerve Fibers, Myelinated/drug effects
  • Nerve Fibers, Myelinated/pathology
  • Neurons/drug effects
  • Neurons/pathology
  • Procainamide/pharmacology*
  • Procainamide/therapeutic use
  • Receptors, Notch/antagonists & inhibitors
  • Sirtuin 1/antagonists & inhibitors
  • Transcription Factors/genetics
  • Transcription Factors/metabolism
  • Vorinostat/pharmacology*
  • Vorinostat/therapeutic use
  • Zebrafish/embryology*
  • Zebrafish/genetics
  • Zebrafish Proteins/genetics*
  • Zebrafish Proteins/metabolism
PubMed
31051269 Full text @ Eur. J. Med. Genet.
Abstract
CHARGE syndrome is an autosomal dominant congenital disorder caused primarily by mutations in the CHD7 gene. Using a small molecule screen in a zebrafish model of CHARGE syndrome, we identified 4 compounds that rescue embryos from disease-like phenotypes. Our screen yielded DAPT, a Notch signaling inhibitor that could ameliorate the craniofacial, cranial neuronal and myelination defects in chd7 morphant zebrafish embryos. We discovered that Procainamide, an inhibitor of DNA methyltransferase 1, was able to recover the pattern of expression of isl2a, a cranial neuronal marker while also reducing the effect on craniofacial cartilage and myelination. M344, an inhibitor of Histone deacetylases had a strong recovery effect on craniofacial cartilage defects and could also modestly revert the myelination defects in zebrafish embryos. CHIC-35, a SIRT1 inhibitor partially restored the expression of isl2a in cranial neurons while causing a partial reversion of myelination and craniofacial cartilage defects. Our results suggest that a modular approach to phenotypic rescue in multi-organ syndromes might be a more successful approach to treat these disorders. Our findings also open up the possibility of using these compounds for other disorders with shared phenotypes.
Genes / Markers
Figures
Expression
Phenotype
Mutation and Transgenics
Human Disease / Model Data
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping
Errata and Notes